克立硼罗价格一览

Introduction: Criborole is a new type of oxaborole, which was approved by the FDA on December 14, 2016. The trade name is Eucrisa and is used to treat mild to moderate atopic dermatitis. This nonsteroidal drug can effectively improve the severity of the disease, reduce the risk of infection, and relieve symptoms and signs in patients 2 years and older. It can reduce local inflammation of the skin and prevent further worsening of the condition, and has a good safety profile.

Price of the original drug of Criborole

It was developed by Anacor Pharmaceuticals Inc., a wholly-owned subsidiary of Pfizer in the United States. It was first approved by the FDA in December 2016. The trade name is Eucrisa. On August 3, 2023, it was approved for marketing on the official website of the China Food and Drug Administration as a topical drug for the treatment of patients with mild to moderate AD aged 2 years and above.

The price of criborole in foreign markets is relatively high. The price of a box is about 1,250 US dollars. According to the current international exchange rate, it is about 9,083$ when converted into RMB. The price is relatively expensive. In China, the winning bid prices for criborole medical insurance are approximately $450, $269, etc.

Prices of generic drugs of Criborole

Currently, only the brand name Criborole produced by the original pharmaceutical company Pfizer is approved for sale. No other pharmaceutical company has been approved to produce generic drugs of Criborole. Therefore, there is no specific price information for generic drugs of Criborole. However, the price of generic drugs is usually lower than that of the original drug, and as market competition increases, the price may be further reduced.

The original drug of Criborole is relatively expensive in the domestic market, but as generic drugs are gradually launched, the price is expected to drop. Patients can pay attention to the launch of relevant generic drugs to obtain more economical treatment options.

The marketing status of criborole in China

On August 3, 2023, the official website of the China Food and Drug Administration announced that Pfizer's criborole ointment was approved for marketing for a new indication, and is speculated to be used for children 3 months and older and adult patients with atopic dermatitis. Criborole is a small molecule, non-hormonal, non-steroidal anti-inflammatory topical phosphodiesterase 4 (PDE-4) inhibitor developed by Anacor as a steroid-free topical therapy to replace steroid therapy.

How to use criborole correctly

It is pointed out that this drug is a topical drug. Apply a thin layer of criborole to the affected area and apply it twice a day. Once the clinical effect is achieved, consider reducing the frequency of administration to once a day. It is important to note that criborole is for topical use only and is not intended for ophthalmic, oral, or intravaginal use.